Get breaking news alerts via email

Click here to manage your alerts
Myriad settles gene patent lawsuit against Texas firm
Litigation » Other battles remain as competitors try to get into testing market.
First Published Feb 07 2014 10:23 am • Last Updated Feb 07 2014 04:39 pm

Salt Lake City-based Myriad Genetics has settled one of a number of lawsuits over gene-related patents it filed against competitors who sprang up after the U.S. Supreme Court invalidated parts of those patents.

Myriad Genetics said Friday it had reached a settlement with Houston-based Gene by Gene Ltd., but Myriad vowed to continue legal battles against other competitors trying to jump into the market.

Join the Discussion
Post a Comment

As part of the settlement, Gene by Gene will stop selling or marketing tests in the United States for the BRCA1 and BRCA2 genes, mutations of which can signal a high risk of breast and ovarian cancer.

But Gene by Gene will be able to continue to offer those tests outside the U.S., as well as selling worldwide products and services linked to the whole genome and portions called exomes that include BRCA tests.

The settlement "is in the best interest of the parties because it ends the uncertainty and expense of ongoing litigation," Myriad spokesman Ron Rogers said in a statement. "Additionally, this deal clears the way for GbG to conduct whole genome and exome testing that will facilitate scientific research and progress."

The agreement is to last until Feb. 12, 2016 or the last expiration of Myriad’s BRCA patents, whichever comes first.

The Supreme Court invalidated portions of the Myriad’s BRCA patents in June of last year, saying products of nature, such as genes, are not eligible for patent protection even when they are isolated from where they naturally occur in the body.

Several companies immediately said they would enter the BRCA testing market. Myriad sued several and itself was sued over efforts to enforce its remaining patent claims.

At least five suits remain pending before U.S. District Judge Robert Shelby in Salt Lake City.

Charles Dunlop, chief executive of Ambry Genetics, one of the companies involved in the litigation, said his company intended to continue the fight to be able to provide patients an alternative to Myriad.

story continues below
story continues below

"We will continue with the litigation and remain confident in the outcome so that Ambry may continue to offer patients a choice in their testing options," he said in an email.

Myriad also intends to continue to try to enforce its patents in those cases, Rogers said.

"Today’s announcement does not include the other patent cases that are pending," he said. "Myriad and the other owners of the BRCA patents at issue — including the University of Utah, the Hospital for Sick Children, Endorecherche, Inc., and the Trustees of the University of Pennsylvania — continue to believe that patent claims related to BRCA1 and BRCA2 gene testing are valid and enforceable and we are prepared to defend our legal rights in those cases."

Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment

About Reader Comments

Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.